reports
Zealand Pharma increases its share capital as a result of the exercise...
Zealand Pharma increases its share capital as a result of the exercise of employee warrants Company announcement – No. 20 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, September 11, 2025 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 20,924 divided into 20,924 new shares ...
SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on...
SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Press release – No.13 / 2025 SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Copenhagen, Denmark, September 11, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it will host a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity. “Obesity is one of ...
Zealand Pharma to participate in upcoming investor conferences in Sept...
Zealand Pharma to participate in upcoming investor conferences in September 2025 Press release – No. 12 / 2025 Zealand Pharma to participate in upcoming investor conferences in September 2025 Copenhagen, Denmark, August 28, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following investor conferences in September 2025. Jefferies Swiss Healthcare Summit 2025, September 3 in Zürich Adam Lange, Vice President, Investo...
- Wim Lewi
AEX from 25 to 30, place your bets Our candidates for the AEX expansio...
The AEX is set to expand from 25 to 30 constituents starting on 23rd September, announcement on 9th September after close. This marks a significant change since its last expansion in 1994. The new rule book was published on 22/08/25 and leaves some room for interpretation for companies that have another primary listing (WDP). We believe that WDP meets the requirement for “reference market”. The expansion will be based on Free Float Market Capitalization, with a buffer zone to manage transitions....
Zealand Pharma major shareholder announcement: Van Herk Investments B....
Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 19 August 2025, Van Herk Investments B.V. (Du...
- Jacob Mekhael
Zealand Pharma 2Q25 results confirm timelines, upcoming CMD in Decembe...
Zealand's 2Q25 results hold no surprises, and show that the company is on track operationally with pipeline timelines being reiterated. While no big data readouts are expected for the remainder of the year, the company is gearing up for a news heavy 1H26 and we most look forward to phase 2b results with petrelintide (amylin analog, partnered with Roche). Zealand reported a cash position of DKK 16,578m, and expects an additional $ 250m in anniversary payments under the Roche agreement in addition...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
Zealand Pharma Announces Financial Results for the First Half of 2025
Zealand Pharma Announces Financial Results for the First Half of 2025 Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche’s Pharma Day in Septe...
Aalberts reports the completion of its share buyback programme
Aalberts reports the completion of its share buyback programme Utrecht, 12 August 2025, Aalberts today reports the completion of the share buyback programme as announced on 27 February 2025, for a total amount of EUR 75 million. The repurchase of shares commenced on 28 February 2025 and completed on 04 August 2025. It is intended that the shares will be cancelled following repurchase. 51,373 of its own shares have been repurchased on 04 August 2025, for an amount of EUR 1,433,068.14, so at an average share price of EUR 27.90 Up to and including 04 August 2025, a cumulative total of 2,54...
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to pre...
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financia...
Aalberts reports the progress of its share buyback programme 28 July ...
Aalberts reports the progress of its share buyback programme 28 July – 01 August 2025 Utrecht, 5 August 2025, Aalberts today reports that it has repurchased 242,722 of its own shares in the period from 28 July 2025, up to and including 02 August 2025, for an amount of EUR 9,756,200, so at an average share price of EUR 28.47. This is part of the share buyback programme as announced on 27 February 2025, for a total amount of EUR 75 million. The repurchase of shares commenced on 28 February 2025 and will be completed no later than 24 October 2025. It is intended that the shares will be canc...
Aalberts reports the progress of its share buyback programme 21 July ...
Aalberts reports the progress of its share buyback programme 21 July – 25 July 2025 Utrecht, 29 July 2025, Aalberts today reports that it has repurchased 145,500 of its own shares in the period from 21 July 2025, up to and including 25 July 2025, for an amount of EUR 4,011,589.94, so at an average share price of EUR 27.57. This is part of the share buyback programme as announced on 27 February 2025, for a total amount of EUR 75 million. The repurchase of shares commenced on 28 February 2025 and will be completed no later than 24 October 2025. It is intended that the shares will be cancel...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Thibault Leneeuw
- Wim Hoste
- Wim Lewi
- Kristof Samoy
Aalberts Model update: 1H25 Results Disappoint; Outlook Cut, Lowered T...
Last Thursday, Aalberts reported 1H25 results that fell short of expectations. Management no longer anticipates a recovery in growth during 2H25 and now guides for a full-year EBITA margin of 13–14% (previously >15%). The 2026 margin target of 16–18% was not reaffirmed. As a result, the stock sharply declined, erasing all gains since the announcement of its intention to acquire the listed Singaporean mechatronics company GVT. Despite the disappointing update, we maintain our Accumulate rating on...
- Kristof Samoy
Aalberts Key Take-aways 1H25 Analyst Call
This morning Aalberts reported 1H25 numbers. Building continued to show a minimal organic growth in 2Q (as in 4Q and 1Q). In Industry the topline decline slowed down to -2.9% and margins benefitted from footprint and cost out initiatives (+90bps q/q). Semicon suffered from an acceleration in the growth decline to -15.5% (2Q) from -11.3% (1Q). Overall, management no longer banks on a growth recovery in 2H25 and expects full year margins to be at 13-14% (previously > 15%). 2026 margin targets (16-...
- Martijn Den Drijver
- ING Helpdesk
Benelux Morning Notes
Aalberts: Light 1H performance, lowers FY25 outlook. Acomo: Hot chocolate. BAM Group: Solid 1H25 performance. BE Semiconductor Industries: 2Q25 results, light at the end of the tunnel. Econocom: 1H25 REBITA in line, net profit hit by €18m loss on discontinued. Orange Belgium: Better 1H25, guidance increased but MSA hurt perception. RELX: 1H25 results – powering ahead. UCB: 1H25 Preview: focus on US expansion.
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thibault Leneeuw
- Wim Lewi
Aalberts N.V.: Aalberts reports first half-year results 2025
Aalberts N.V.: Aalberts reports first half-year results 2025 Utrecht, 24 July 2025 highlights(before exceptionals) revenue EUR 1,557 millionorganic revenue decline 3.2%EBITA EUR 210 million; EBITA margin 13.5%earnings per share before amortisation EUR 1.38free cash flow EUR 56 million CEO statement“Our performance for the first half of the year has been impacted by the continued softness of our end markets, mostly automotive and semicon, and increased uncertainties due to global trade policies, leading to an organic revenue decline in our industry and semicon segments. We sustained our...
Aalberts reports the progress of its share buyback programme 14 July –...
Aalberts reports the progress of its share buyback programme 14 July – 18 July 2025 Aalberts today reports that it has repurchased 2,500 of its own shares in the period from 14 July 2025, up to and including 18 July 2025, for an amount of EUR 80,592.48, so at an average share price of EUR 32.24. This is part of the share buyback programme as announced on 27 February 2025, for a total amount of EUR 75 million. The repurchase of shares commenced on 28 February 2025 and will be completed no later than 24 October 2025. It is intended that the shares will be cancelled following repurchase. Up ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.